SNORA16B: A Potential Drug Target and Biomarker (G692157)

Target Name: SNORA16B

NCBI ID: G692157

SNORA16B

Other Name(s): small nucleolar RNA, H/ACA box 16B | Small nucleolar RNA, H/ACA box 16B | U98b

SNORA16B: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a critical role in various cellular processes, including gene expression and regulation. In humans, there are many types of snRNA, among which H/ACA box 16B (H/ACA box 16B) is a gene that causes various diseases. In recent years, researchers have conducted in-depth studies on SNORA16B and discovered its potential role in drug development and disease treatment. This article will discuss the biological functions, drug targets, and clinical application prospects of SNORA16B.

1. Biological functions of SNORA16B

SNORA16B is a 29.4-nucleotide snRNA located in the H/ACA box 16B region of the human genome. It is mainly composed of two main components: core RNA and tail RNA. Core RNA is composed of 7-9 nucleotides, and tail RNA is composed of multiple nucleotides. The main function of SNORA16B is to bind DNA and participate in gene expression and regulation.

In cells, SNORA16B is often associated with nucleoli. The nucleolus is a structure in the nucleus that is mainly involved in the formation and function of ribosomes. SNORA16B interacts with nucleolar proteins and contributes to ribosome assembly and RNA processing. In addition, SNORA16B can also bind to DNA and affect gene expression and regulation.

2. Drug targets of SNORA16B

SNORA16B, as an RNA-binding protein, can be used as a drug target. At present, researchers have discovered multiple drug targets related to SNORA16B. These targets include:

1. RPGM2 (ribosome light chain binding protein 2): RPGM2 is a protein that interacts with SNORA16B and can inhibit the binding of SNORA16B to ribosomes, thereby inhibiting protein synthesis.

2. HSP70 family: The HSP70 family is an important class of proteins that can bind a variety of substrates, including SNORA16B. Members of the HSP70 family can inhibit the binding of SNORA16B to substrates, thereby inhibiting gene expression.

3. ARF6 (Histone Modifier 6): ARF6 is a protein that can bind to SNORA16B, thereby affecting histone modification and gene expression.

4. MBP (histone binding protein): MBP is a protein that can bind SNORA16B, thereby affecting histone modification and gene expression.

5. NF-E2F2 (transcription factor E2F2): NF-E2F2 is a transcription factor that can bind SNORA16B and thereby participate in gene expression and regulation.

3. Clinical application prospects of SNORA16B

As a new drug target, SNORA16B has an important potential role in drug development and disease treatment. Currently, researchers are exploring the application of SNORA16B in the treatment of cancer, neurodegenerative diseases, etc.

1. Treat cancer: SNORA16B plays an important role in tumor occurrence and development. Studies have shown that the expression level of SNORA16B is related to tumor invasion and metastasis. Therefore, by inhibiting the activity of SNORA16B, tumor growth and metastasis can be inhibited. Currently, researchers are exploring the use of SNORA16B as a new way to treat cancer.

2. Treatment of neurodegenerative diseases: SNORA16B plays an important role in neurodegenerative diseases. For example, SNORA16B is closely associated with neuronal death and synapse loss in neurodegenerative diseases. Therefore, by inhibiting the activity of SNORA16B, neurodegenerative diseases can be treated. at present,

Protein Name: Small Nucleolar RNA, H/ACA Box 16B

The "SNORA16B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA16B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets